Optic Nerve Progenitor Cell Factors for Glaucoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma primarily focus on reducing intraocular pressure, which is only partly effective, and there is a need for alternative and supplemental treatments to address the complex pathophysiology of glaucoma.
Innovation Solution
The use of optic nerve lamina region neural progenitor cells (ONLR-NPCs) and their secreted factors, such as growth and survival factors, to promote ocular health and function, potentially replacing these factors to improve glaucoma treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments focus only on intraocular pressure reduction, then the treatment approach is simple and easy to implement, but the treatment effectiveness is only partly successful and does not address the complex pathophysiology of glaucoma
Solution Approach 1:
The treatment approach is segmented into multiple components: (1) continued intraocular pressure reduction to maintain the primary benefit of current treatments, and (2) addition of growth factor therapy to address the specific pathophysiological deficiency of neurotrophic factor loss. This segmentation allows each treatment component to target specific aspects of the disease without requiring complete redesign of the existing effective pressure-lowering approach.
Solution Approach 2:
The patent merges two distinct treatment strategies: the established pressure-lowering treatments and the novel growth factor replacement therapy. By combining these approaches, the treatment addresses both the mechanical aspect (pressure) and the biological aspect (neurotrophic support) of glaucoma pathophysiology, thereby improving overall treatment effectiveness while building upon rather than replacing existing successful interventions.
2Reliability
If alternative and supplemental treatments addressing complex pathophysiology are developed, then treatment effectiveness is improved, but the treatment approach becomes more complex
Solution Approach 1:
The patent introduces growth factors as intermediary substances that mediate between the administered treatment and the damaged optic nerve tissue. These growth factors act as biological messengers that replenish the lost neurotrophic support, enabling the treatment to address complex pathophysiological mechanisms through a natural biological pathway rather than requiring direct complex interventions on the nerve tissue itself.
Data Source
AI summary
Optic nerve lamina region neural progenitor cells (ONLR-NPCs) are provided. Such cells secrete growth factors and survival factors that can be used in the treatment of optic nerve diseases, such as glaucoma. Also provided are methods of treating or preventing optic nerve diseases, such as glaucoma, using one or more factors secreted by ONLR-NPCs, combinations of factors secreted by ONLR-NPCs, or culture media conditioned by ONLR-NPCs.